November 18, 2026
Health news, explained with evidence
LIVE

Study Identifies Molecular Axis Driving Tumor Growth and Immune Evasion in Liver Cancer

🥗 Nutrition 2 min read 👁 3

Researchers in China have discovered that a specific RNA-binding protein promotes tumor progression and immune suppression in hepatocellular carcinoma by regulating the SERPINH1 gene.

🥗Nutrition

Key points

  • SRSF3 protein is upregulated in human hepatocellular carcinoma tissues and linked to poor prognosis.
  • The factor binds to SERPINH1 mRNA, boosting its expression and promoting fibrosis and immune evasion.
  • Preclinical findings suggest targeting this axis could eventually guide new treatment strategies.

A new study published in Nature Health Sciences has identified a molecular mechanism that drives the aggressive progression of hepatocellular carcinoma (HCC), the most common form of liver cancer. Investigators at the General Hospital of Ningxia Medical University found that an RNA splicing factor known as SRSF3 is heavily upregulated in liver tumor tissues, linking its presence to a poor clinical prognosis. Through laboratory analyses and animal models, the research team demonstrated that elevated levels of SRSF3 encourage cancer cell multiplication, tissue invasion, and the suppression of the body's natural immune response against the tumor.

The study notes that SRSF3 operates by directly binding to and increasing the expression of SERPINH1 messenger RNA. In particular, a shorter isoform of SERPINH1 was found to trigger robust pro-tumorigenic and pro-fibrotic effects, enhancing collagen buildup and preventing cytotoxic immune cells from infiltrating the tumor microenvironment. While these findings offer valuable mechanistic insights into how liver cancers evade immune detection, the authors emphasize that the research remains in early stages, relying on cellular and animal models that require further clinical validation before any therapeutic applications can be developed.

What to know: Researchers have linked the SRSF3–SERPINH1 protein axis to increased tumor growth and immune evasion in liver cancer, suggesting it could eventually serve as a target for new therapies. However, this is early-stage laboratory research and does not constitute medical guidance. Always consult a qualified healthcare provider for personal health and treatment decisions.

Source Nature Health Sciences — nature.com/articles/s41598-026-71568-1 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.